An observational study in Obesity, sponsored by Singapore General Hospital. Completed at 1 site in Singapore. Open to participants aged 21 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Singapore General Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies in Obesity with a site in Singapore — 17 open to participants now, 25 under way, 1 of them phase 3. Obesity · Singapore.
Among the 83 studies in Obesity with a site in Singapore, this one is the 9th largest by enrollment of the 15 observational ones that give a count, is one of 8 that started in 2025, is one of 15 observational ones, and was the 69th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →17 of the 83 studies in Obesity with a site in Singapore are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Singapore, United States
Ages 18–65
Eli Lilly and Company · Sites in Singapore, United States
Ages 18–65
Eli Lilly and Company · Sites in Singapore, United States
Ages 18–65 · Healthy volunteers
National University of Singapore · Sites in Singapore
Ages 21–70 · Healthy volunteers
Eli Lilly and Company · Sites in Singapore, United States
Ages 18–65 · Healthy volunteers
A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 21 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 4 · Phase 3 5 · Phase 4 4
First in 2005; this study’s year is marked. 8 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 160 is above the median of 115 across 2,159 observational studies indexed under Obesity.
Median enrollment 70 across the 68 interventional studies, 200 across the 15 observational. Of the 45 that completed or were terminated, 2 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 83 have an industry lead sponsor. The 10 most frequent:
Singapore General Hospital is the lead sponsor of 270 studies on the registry; 57 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Singapore General Hospital has 4 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
9 of the studies in Obesity with a site in Singapore that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07299084Eli Lilly and CompanyA Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus | 2026-11 |
| NCT07738614Eli Lilly and CompanyA Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight | 2026-12 |
| NCT07225556Eli Lilly and CompanyA Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy | 2026-12 |
| NCT07444073National University of SingaporeAssessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical Clock | 2026-12-31 |
| NCT06363253Sengkang General HospitalPilot Study of the Human Metagenome in Metabolic Diseases | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 83 studies in Obesity with a site in Singapore, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Sarcopenia, a condition where individuals lose muscle mass and strength, is associated with poorer health and function. While aging is a well-known cause of sarcopenia, obesity is increasingly recognised as a significant factor. When sarcopenia and obesity occur together, it can result in more severe health problems. This is especially concerning because weight loss, the treatment for obesity, can further reduce muscle mass and potentially worsen the situation. Despite this, it is unknown how common sarcopenia is among people with obesity, as only a few studies have looked into this using the most accurate diagnostic criteria, showing a prevalence of 4-13%.
In this study, the investigators will examine the prevalence of sarcopenia in 300 adults with obesity at a specialized Obesity Center. The investigators expect to find a higher prevalence among Asian participants due to differences in body composition compared to other ethnic groups.
The investigators will also explore various factors that might be linked to sarcopenia in these individuals, such as age, gender, race, body mass index, smoking and alcohol use, medical conditions, medications, physical activity, aerobic capacity, and dietary protein intake. Some of these factors could help in identifying those at risk of sarcopenia and could be targeted for future treatments.
Currently, screening for sarcopenia is not a standard part of routine obesity care as it requires specialized equipment and trained staff. By determining how common sarcopenia is in people with obesity, this study will help healthcare providers better understand the problem and allocate resources effectively. Identifying factors associated with sarcopenia will also help streamline diagnosis and monitoring for those at risk.
Adults with obesity seeking treatment at Singapore General Hospital Obesity Centre
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sarcopenia
Skeletal muscle mass Skeletal muscle mass measurement will be obtained via bioimpedance analysis using the TANITA MC 780 MA Multi-frequency Segmental Body Composition Analyser. Low skeletal muscle mass will be defined by percentage of skeletal muscle mass divided by body weight of ≤ 37% in males and ≤ 27.6% in females.
Time frame: Outcome measures will be recorded at baseline only.
Handgrip strength
Handgrip strength will be measured using the Jamar handgrip dynamometer. Two trials will be performed for each hand, and the maximum strength will be used for diagnosis.
Time frame: Outcome measures will be recorded at baseline only.
5-time chair stand test
Time taken (seconds) to perform 5 sit-to-stand repetitions
Time frame: Outcome measures will be recorded at baseline only.
30-second sit-to-stand test
Number of sit-to-stand repetitions performed in 30 seconds
Time frame: Outcome measures will be recorded at baseline only.
Aerobic capacity
The study will use a validated non-exercise prediction model comprising a physical activity questionnaire to estimate peak oxygen uptake, VO2 milliliter/kg/minute (ml/kg/min). This simple physical activity questionnaire consists of age, gender, height, weight, estimated maximum heart rate, frequency of exercise, length of time for each workout, intensity of each workout, waistline diameter, and resting heart rate. It will be self-administered or administered with the assistance of the clinical research coordinator if required.
Time frame: At baseline
Physical activity questionnaire
Number of minutes per week spent on moderate to vigorous physical activity will be recorded
Time frame: At baseline
Dietary questionnaire
72 hour dietary recall questionnaire will be administered and dietary macronutrient composition will be calculated
Time frame: At baseline
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from May 2025 to primary completion in May 2026, 12 months.
Completion moved once since we started tracking on Sep 25, 2026: Apr 2027 → Jul 2026, on Oct 27, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.